| Active substance | Zolbetuximab |
| Holder | Astellas Pharma Global Development, Inc. |
| Status | closed |
| Indication | Zolbetuximab in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive. |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 17/12/2025 |